Overcoming the "Sweet Burden": Preclinical Gaa KO Models for Pompe Disease

Pompe Disease: The Burden of Glycogen Accumulation

What happens when glycogen—normally a vital energy reserve—turns into a progressive and destructive burden within muscle cells?

This is the reality of Pompe disease, a rare inherited lysosomal storage disorder, also known as glycogen storage disease type II (GSD II) ^[1].

Pompe disease is characterized by progressive muscle weakness and respiratory dysfunction. In its most severe infantile-onset form (IOPD), patients often develop hypertrophic cardiomyopathy and respiratory failure within the first months of life, while late-onset Pompe disease (LOPD) presents later with gradual skeletal muscle and respiratory involvement ^[1–3].

Figure 1. Clinical manifestations of Pompe disease, highlighting motor impairment and respiratory dysfunction.

The Molecular Mechanism: GAA Deficiency and Lysosomal Glycogen Accumulation

Pompe disease is caused by pathogenic variants in the GAA gene, which encodes acid α-glucosidase (GAA)—the lysosomal enzyme responsible for glycogen degradation.

Loss or dysfunction of GAA leads to progressive glycogen accumulation within lysosomes, resulting in lysosomal swelling, cellular damage, and eventual dysfunction of cardiac, skeletal, and respiratory muscles ^[1–2].

The global incidence of Pompe disease is estimated at approximately 1 in 40,000 births. Disease severity correlates strongly with residual GAA activity and age of onset ^[1–3].

Figure 2. Pathophysiological mechanism of Pompe disease caused by GAA deficiency.

Therapeutic Landscape: From Enzyme Replacement to Gene Therapy

Enzyme replacement therapy (ERT) remains the current standard of care. Recombinant human GAA (rhGAA), such as alglucosidase alfa (Myozyme® / Lumizyme®), can slow disease progression and improve survival [3–5]. However, important limitations remain, including:

• Antibody-mediated immune responses
• Suboptimal tissue uptake
• Limited effects on neuromuscular pathology
• High lifelong treatment costs

As a result, multiple next-generation therapeutic strategies are actively under investigation [6–12]:
Gene therapy (primarily AAV-based) aiming for sustained endogenous GAA expression
Next-generation ERTs with improved targeting and pharmacokinetics
Substrate reduction therapy (SRT) to limit glycogen synthesis

Figure 3. Mechanisms of action of emerging Pompe disease therapies at the cellular level.

The Value of Gaa Knockout Mice in Pompe Disease Preclinical Research

Robust translational research depends on disease models that faithfully recapitulate human pathology. The Gaa knockout (Gaa KO) mouse exhibits high genetic and functional relevance to human Pompe disease. These mice demonstrate:

• Near-complete loss of GAA enzymatic activity
• Progressive glycogen accumulation in heart and skeletal muscle
• Muscle weakness and functional impairment

This model has been widely used to study disease mechanisms and to evaluate the efficacy of ERT, RNA interference strategies, and AAV-mediated gene therapies [12–15].

Figure 4. Representative preclinical application of Gaa KO mice in Pompe disease therapeutic evaluation.

Cyagen Gaa KO Mouse Model: Scientifically Validated and Translationally Relevant

To support high-quality Pompe disease research, Cyagen has developed a Gaa KO mouse model (ID： C001702).

Key validated phenotypes of Gaa KO Mouse Model:

（1）Reduced muscle strength

Gaa KO mice show significantly decreased grip strength compared with wild-type controls.

Figure 5. Grip strength assessment in 12-week-old homozygous female Gaa KO mice vs. WT controls.

（2）Increased body weight

At 12 weeks of age, Gaa KO mice exhibit higher body weight relative to WT mice.

Figure 6. Body weight comparison between Gaa KO and WT mice (12 weeks, female).

（3）Severe glycogen accumulation

Glycogen levels are dramatically elevated in the heart and gastrocnemius muscle of Gaa KO mice—approximately 33-fold higher in the heart and 2-fold higher in skeletal muscle compared with WT controls.

Figure 7 .Glycogen quantification in heart and gastrocnemius muscle.

（4）Loss of GAA enzymatic activity

GAA activity in both cardiac and skeletal muscle is reduced to approximately 10% of WT levels.

Figure 8 . GAA enzymatic activity measurements in heart and gastrocnemius muscle.

Accelerating Pompe Disease Research & Drug Discovery

Collectively, the Cyagen Gaa KO mouse model (C001702) faithfully recapitulates the defining pathological hallmarks of Pompe disease, including GAA deficiency, lysosomal glycogen accumulation, and muscle dysfunction. With stable phenotypes and reproducible data, this model provides a powerful platform for:

• Disease mechanism studies
• Drug screening and efficacy evaluation
• Preclinical validation of ERT, gene therapy, and novel therapeutic strategies

At Cyagen, we remain committed to delivering scientifically rigorous disease models that accelerate translational research and bring innovative therapies closer to patients.

Reference

[1] Sanofi. (2023, February 24). Pompe - Sanofi campus. Retrieved from https://www.campus.sanofi/bh/science/rare-diseases/cutting-edge-science/2023/ar/pompe

[2] Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471-86.

[3] Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021 Dec;20(12):1027-1037.

[4] Singh, A., Debnath, R., Saini, A., Seni, K., Sharma, A., Bisht, D. S., Chawla, V., & Chawla, P. A. (2024, June). Cipaglucosidase alfa-atga: Unveiling new horizons in Pompe disease therapy. Health Sciences Review, 11, 100160. Retrieved from https://www.sciencedirect.com/science/article/pii/S2772632024000138

[5] Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021 Dec;20(12):1012-1026.

[6] Bolano-Diaz C, Diaz-Manera J. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management. Ther Clin Risk Manag. 2022 Dec 13;18:1099-1115.

[7] Koeberl DD, Koch RL, Lim JA, Brooks ED, Arnson BD, Sun B, Kishnani PS. Gene therapy for glycogen storage diseases. J Inherit Metab Dis. 2024 Jan;47(1):93-118.

[8] Bond JE, Kishnani PS, Koeberl DD. Immunomodulatory, liver depot gene therapy for Pompe disease. Cell Immunol. 2019 Aug;342:103737.

[9] Sawada T, Kido J, Nakamura K. Newborn Screening for Pompe Disease. Int J Neonatal Screen. 2020 Apr 5;6(2):31.

[10] Salabarria SM, Nair J, Clement N, Smith BK, Raben N, Fuller DD, Byrne BJ, Corti M. Advancements in AAV-mediated Gene Therapy for Pompe Disease. J Neuromuscul Dis. 2020;7(1):15-31.

[11] Stevens D, Milani-Nejad S, Mozaffar T. Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview. Curr Treat Options Neurol. 2022 Nov;24(11):573-588.

[12] Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B, Plotz P. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem. 1998 Jul 24;273(30):19086-92.

[13] Raben N, Nagaraju K, Lee E, Plotz P. Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul Disord. 2000 Jun;10(4-5):283-91.

[14] Fusco AF, McCall AL, Dhindsa JS, Zheng L, Bailey A, Kahn AF, ElMallah MK. The Respiratory Phenotype of Pompe Disease Mouse Models. Int J Mol Sci. 2020 Mar 24;21(6):2256.

[15] Holt BD, Elliott SJ, Meyer R, Reyes D, O'Neil K, Druzina Z, Kulkarni S, Thurberg BL, Nadler SG, Pederson BA. A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. Mol Ther. 2025 Jan 8;33(1):235-248.